Masayuki Tanaka

Dr. Masayuki Tanaka


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YEYutaka Endo
Yutaka Endo
MTMasayuki Tanaka
Masayuki Tanaka
MKMinoru Kitago
Minoru Kitago
HYHiroshi Yagi
Hiroshi Yagi
YAYuta Abe
Yuta Abe
YKYuko Kitagawa
Yuko Kitagawa

16 June 2025 in Livers
Verified
Journal Article
Open access
PDF file
SUSho Uemura
Sho Uemura
YHYasushi Hasegawa
Yasushi Hasegawa
HOHideaki Obara
Hideaki Obara
MKMinoru Kitago
Minoru Kitago
HYHiroshi Yagi
Hiroshi Yagi
YKYuko Kitagawa
Yuko Kitagawa
Background: De novo malignancies (DNMs) after liver transplantation (LT) are a major cause of long-term mortality. However, no definitive screening protocol has been established due to their diversity. This study aimed to evaluate DNM diagnosis methods, screening protocols, and prognoses. Methods: This retrospective study included 231 adult LT recipients from April 1997 to March 2021. Disease-specific survival (DSS) was analyzed to assess the impact of screening on prognosis. Most recipients underwent serum tests every three months, annual gastrointestinal endoscopy, and chest-abdominal CT as part of routine surveillance. Results: Twenty-five DNMs were diagnosed in 22 patients, with median age of 61 years (range, 23–72), of whom 13 (59.1%) were female. The duration from transplantation to DNM diagnosis of DNM was 88 months (range, 4–195). DNM was diagnosed as follows: seven patients (31.8%) through screening (screening group) and 15 patients (68.2%) by other means (non-screening group). Curative treatment was achieved in all of the patients diagnosed by screening, whereas it was possible in only 60.0% of patients diagnosed by other means (p = 0.026). DSS in the screening group was significantly longer than that in the non-screening group (p = 0.024). Conclusions: While screening was associated with earlier-stage diagnosis and improved outcomes in some patients, the overall efficacy of the protocol requires further validation in larger studies.

1 August 2024 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
Yutaka EndoYutaka Endo
Yutaka Endo
YAYuta Abe
Yuta Abe
MKMinoru Kitago
Minoru Kitago
YHYasushi Hasegawa
Yasushi Hasegawa
SHShutaro Hori
Shutaro Hori
YKYuko Kitagawa
Yuko Kitagawa
Hepatocellular carcinoma (HCC) in the caudate lobe presents surgical challenges due to the lack of distinct anatomical landmarks. This case report introduces a novel surgical approach combining Takasaki’s classification and indocyanine green negative counterstaining for precise anatomical caudate lobectomy. A 78-year-old patient with hepatocellular carcinoma in the caudate lobe underwent surgery following preoperative volumetric assessment. The method involved a glissonian approach for both left and right pedicles, coupled with meticulous dissection of hepatic pedicles of the caudate lobe guided by taping of left and right glissonian pedicles, followed by indocyanine green administration for improved visualization of caudate lobe boundaries. The procedure enabled complete tumor resection with minimal blood loss. At 50 months postsurgery, the patient maintains favorable liver function and performance status. This innovative approach offers a promising solution for precise resection of caudate lobe hepatocellular carcinoma, potentially improving surgical outcomes and long-term prognosis.

18 August 2025 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
SUSho Uemura
Sho Uemura
MTMasayuki Tanaka
Masayuki Tanaka
MKMinoru Kitago
Minoru Kitago
HYHiroshi Yagi
Hiroshi Yagi
YAYuta Abe
Yuta Abe
YKYuko Kitagawa
Yuko Kitagawa
Background: Chemotherapeutic advances have increased opportunities for conversion surgery (CS) in unresectable locally advanced (UR‐LA) pancreatic cancer (PC). However, the optimal indications for CS remain unclear. Sarcopenia has been associated with poor outcomes in PC, except UR‐LA PC. Herein, we aimed to evaluate the impact of sarcopenia on the prognosis of patients with UR‐LA PC. Methods: In this retrospective study, we reviewed consecutive patients with UR‐LA PC who had received chemo(radio)therapy as an initial treatment between 2015 and 2023. We examined relevant clinical variables and CT findings at initial diagnosis and at 6 months after starting treatment. Results: Ten of the 41 patients had undergone CS. Tumor size at 6 months, clinical lymph node metastasis at diagnosis, and changes in sarcopenia over 6 months were associated with overall survival (OS) (multivariate analysis: hazard ratio = 3.25, 2.79, and 3.51, respectively). In the entire cohort, patients without any of these three factors had significantly better OS than those with one or more (median OS: 30.3 months vs. 17.3 months, p = 0.013). CS was associated with better OS among patients without these factors (not reached vs. 25.5 months, p = 0.039), but not in those with one or more. Conclusions: The impact of change in sarcopenia on prognosis was demonstrated in patients with UR‐LA PC. Although, given the limited number of cases, CS might provide a survival benefit in carefully selected patients without prognostic factors such as tumor size at 6 months, clinical lymph node metastasis at diagnosis, and the rate of change of the psoas muscle mass index (PMI).

29 September 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MTMasayuki Tanaka
Masayuki Tanaka
MHMax Heckler
Max Heckler
AMAndré L. Mihaljevic
André L. Mihaljevic
SEShigenori Ei
Shigenori Ei
UKUlla Klaiber
Ulla Klaiber
Thilo HackertThilo Hackert
Thilo Hackert